{"brief_title": "Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma", "brief_summary": "The objective is to determine the safety and efficacy of dexosome immunotherapy in patients with Stage IV malignant melanoma", "condition": ["Melanoma"], "intervention_type": ["Biological"], "intervention_name": ["autologous dexosomes loaded with tumor-specific peptides"], "criteria": "- Patients with Stage IV metastatic melanoma with 0-1 prior treatments for metastatic disease. - All patients must have distant skin, subcutaneous, or nodal metastases (M1a) or lung metastases (M1b), measurable disease, normal lactate dehydrogenase levels, and HLA type A1, A2, or B35. - Patients must have adequate organ function and an estimated life expectancy of at least 3 months.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Melanoma"], "id": "NCT00042497"}